Enfuvirtide Acetate (T-20)
alias:Fuzeon
Sequentia:CH3CO-Tyr-Thr-Ser-Leu-Ile-His Ser-Leu-Ile-Glu-Ser-Gln-Asn-Gln-Glu-Lys-Asn-Glu-Gln-Leu-Leu- Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Cas No. : 159519-65-0
Formulae hypotheticae : C204H301N51O64
M. Pondus : 4492
Puritas (HPLC) : 98.0%min.
Aspectus : Alba ut off-album amorpho solidum
una immunditia (HPLC) : 0.5%max
Amino Acidum Compositio : ± X% speculationis
Peptide Content (N%) : ≥80.0%
Aqua Content (Carolus Fischer) : ≤8.0%
TrifluoroAcetate Content(HPIC) : ≤12.0%
MS (ESI) : Congruunt
Massa Libra : 95.0~105.0%
Gradus : Pharmaceutical Grade
Repono: Clausa, infra 2 ~ 8℃ conservatio
Consuetudinem : Curatio optionis pro aegris laborantibus HIV / SCDI.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtide (TABERNA) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
